Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2021 | Story Nonsindiso Qwabe | Photo Supplied
Dr Samantha Potgieter.

As COVID-19 vaccines continue to be a topical issue in South Africa and indeed in the world itself, the Department of Human Resources held a webinar for the UFS community on 10 September that delved deeper into the questions surrounding the vaccine. 

Dr Samantha Potgieter, infectious disease expert at the Universitas Academic Hospital and affiliated Lecturer in the Department of Internal Medicine at the University of the Free State, addressed some commonly raised concerns about the COVID-19 vaccine and how it affects us.

Dr Potgieter started off by saying that coronaviruses have been causing outbreaks among humans for millennia. While COVID-19 is relatively mild and self-limiting in 80% of patients, 20% of patients are at risk of developing severe disease.
She said before a vaccine could be introduced to a population, it had to go through rigorous testing and clinical trials. Only once safety has been confirmed, it can be released and distributed. 

“This process usually takes about ten years; this is what we are used to. But it has happened much quicker for the COVID-19 vaccine, and I think this is a fact that many people misinterpret – that the evidence might not be that robust, which is certainly not the case. COVID-19 vaccines have gone through all this rigorous testing, thousands of patients had volunteered for trial testing studies. The point is that we already had the technology, vaccination is not something new to humans. So, these preclinical trials were able to happen very quickly, and because of the large number of infections and because the focus of the entire world was on finding a cure, it was a very set process to get these trials through the adequate phases.” 

She said the COVID-19 vaccine was approved by national regulators, manufactured to exacting standards, and only thereafter distributed – as is the case for all drugs released into the market.

How does the vaccine work?

Dr Potgieter said the vaccine works by producing antibodies against the COVID-19 virus. If you are infected with the COVID-19 virus after getting vaccinated, these antibodies bind to the virus and stop it from replicating.

“When you get infected with a disease such as COVID-19, natural antibodies are produced by the immune system to fight the disease. If you get infected again, the immune system will remember how to respond, and quickly destroy the virus. A vaccine can do the same, but without the risk of disease from natural infection. Vaccines work by imitating a bacteria or virus using either mRNA in the case of the COVID-19 vaccine, or a dead or weakened version of the bacteria or virus. The vaccine raises the body’s alarm. It trains the body to recognise and fight the virus. When the body encounters the real-deal virus, it is primed and ready to fight for the body’s health.”

She said South Africa had the mRNA vaccine in the form of the Pfizer vaccine, and the adenoviral vector vaccine in the form of the Johnson & Johnson vaccine.

Why should you get the vaccine?

Dr Potgieter said vaccines are safe and effective, and the most compelling reasons for getting vaccinated are the following:

-To protect yourself from severe disease
-To protect those around you who may be at risk of severe disease
-To restore the social and economic platforms of the country, and the world at large.
She said that while the vaccine does not prevent you from getting COVID-19, it offers better protection against the development of severe disease, and vaccinated people had 50% less chance of spreading the virus.
The most common side effects of the vaccine are the following:
-Pain at the injection site
-Swollen lymph nodes
-Fever
-Fatigue
-Headache
-Myalgia (muscle pain)

“These are indications that the immune system is mounting a response. When it mounts a response, it produces antibodies,” she said.

Answers to commonly asked questions are the following:

1. Can the vaccine alter my DNA?
“No, it goes nowhere near the nucleus of the cell.”

2. What happens when you get COVID in between the first and second doses?
“Some protection is conferred after the first dose, but maximum protection is conferred two weeks after the second dose. Vaccination is still advised.” 

Dr Potgieter said patients who were between vaccinations still show better recovery results than those without.

3. What about natural immunity?
“Natural immunity might confer better protection, but it runs the risk of severe disease. Yes, immunity can be gained through natural immunity, it can be gained through vaccination, and it can certainly be gained by a combination of the two.”

4. What about long-term side effects?
“Serious side effects that cause long-term health problems following any vaccination are very rare, including the COVID-19 vaccination.”

To get the answers to more of your questions, the webinar can be accessed via the following link: https://event.webinarjam.com/go/replay/43/053q6a8vay9a0qa2

News Archive

From music to theology: Stats Unit valuable in research process
2017-02-23

Description: Prof Robert Schall Tags: Prof Robert Schall

Prof Schall, head of the UFS Statistical Consultation Unit
Photo: Leonie Bolleurs

Whether it is analysing data on church attendance, climate change in the Northern Cape or injuries among elite female hockey players, the Statistical Consultation Unit at the University of the Free State (UFS) can assist researchers from the planning of research to publication therof.

Many students and researchers think that the time to consult a statistician is after their research data has been collected. According to Prof Robert Schall, head of the unit, the most significant contribution a statistician can make to a research project is often during its planning. Preferably all researchers should consult the unit early in the research process.

Statistical consultation service free for postgraduates

The consultation unit, established in 2014 in the Department of Mathematical Statistics and Actuarial Science, provides support to all UFS researchers. This service is rendered to postgraduate students at no charge.

“The unit can make a contribution throughout the research process, from the planning of the research project, through the analysis of research data, up to the publication of the findings. I have been involved in projects where, for example, a few very simple changes to the design of a questionnaire would have saved the researcher and the statistician a lot of trouble. It will be beneficial for researchers to have their questionnaires and study proposals (where relevant), reviewed by a statistician,” Prof Schall said.

“The unit can make a contribution
throughout the research process,
from the planning of the research
project, through the analysis of
research data, up to the publication
of the findings.”

Fascinating research topics deliver fascinating data
The professor assisted in a study for the Department of Soil, Crop and Climate Sciences to determine whether rainfall in the Northern Cape had changed over the past 90 years, potentially indicating climate change.

Other interesting projects he has worked on came from the Department of Exercise and Sport Sciences. “Who will not be fascinated by data sets on aspects of rugby, cricket or even netball? One significant finding was a predictor of injury in elite female hockey players. The PhD student identified a pre-season test which predicted the occurrence of an in-season injury with 100% specificity and 100% sensitivity. The finding was quite surprising, and, if the results can be replicated, obviously would be useful in the prevention of injuries,” he said.

This is, of course, not an exhaustive list of projects the unit has worked on. “Not in my wildest dreams would I have expected to be involved in projects coming from the Faculty of Theology, or from the Odeion School of Music,” Prof Schall said.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept